Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06193616

Outcome of ADPKD With Octreotide LAR

Sponsor: Mario Negri Institute for Pharmacological Research

View on ClinicalTrials.gov

Summary

In this observational, retrospective study we will primarily aim at evaluating the independent role of baseline clinical and laboratory parameters, including TKV, in the prediction of long term chronic GFR decline and other clinical outcomes and, secondarily, the relationships between GFR and TKV changes over time, in a cohort of ADPKD patients with Stage IV CKD on chronic treatment with octreotide LAR and routinely monitored with serial GFR, TKV and clinical evaluations, at the outpatient clinic of the Nephrology Unit of the Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.

Official title: Evaluating Baseline Predictors Including Total Kidney Volume, of Chronic GFR Decline and Other Clinical Outcomes in Outpatients With ADPKD and Stage IV CKD on Chronic Treatment With Octreotide LAR: a Retrospective, Observational Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

70

Start Date

2024-02-12

Completion Date

2025-12

Last Updated

2025-09-05

Healthy Volunteers

No

Interventions

DRUG

Octreotide

All consenting patients treated with octreotide LAR according to Determina AIFA n. 1264 del 3 August 2018 and fulfilling the selection criteria will be collected at prespecified time-points according to the routine visits scheduled for these patients and the periodic follow-up visits till dialysis initiation as described in the AIFA indication on GU Serie Generale n.5 del 08-01-2020.

Locations (1)

ASST HPG23 - Unità di Nefrologia

Bergamo, BG, Italy